Action Potential Venture Capital
Action Potential Venture Capital, established in 2013 and based in Cambridge, Massachusetts, is the venture capital arm of GlaxoSmithKline. With a focus on bioelectronic medicines, the fund seeks to invest in companies that are pioneering innovations in this emerging field. It aims to build a portfolio of five to seven companies over the next five years, concentrating on three key areas: new start-ups dedicated to bioelectronic medicine, existing firms that utilize first-generation devices to interact with the peripheral nervous system, and companies developing foundational technology platforms for these treatments. The fund's first investment was in SetPoint Medical, which specializes in implantable devices for treating inflammatory diseases. Imran Eba has been appointed as the first partner, transitioning from GSK’s Worldwide Business Development organization to work closely with the Bioelectronics R&D unit. Through strategic investments, Action Potential Venture Capital aims to advance the development of therapies that can communicate with the body's electrical signals to address various health conditions.
Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform. Its novel neuromodulation platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback.
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
Axon Therapies developed the SAVM procedure. Their novel approach to modulating the body’s sympathetic nervous system to restore balance in the circulatory system.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform. Its novel neuromodulation platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback.
Cala Health is a bioelectronic medicine company focused on developing wearable neuromodulation therapies for chronic diseases. The company integrates neuroscience and technology to provide individualized peripheral nerve stimulation. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor. Cala Health is also working on therapies for Parkinson's disease and other neurological conditions and areas in psychiatry, cardiology, and autoimmune disorders.
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.